{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cai W"],"funding":["All of Us Research Program (Precision Medicine Initiative Cohort Program)","Geoffrey Beene Cancer Research Center","All of Us Research Program","Center for Experimental Therapeutic of MSK","NCI NIH HHS","Edward P. Evans Foundation"],"pagination":["1361-1379"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11444887"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(10)"],"pubmed_abstract":["Chimeric antigen receptor (CAR) T-cell therapy has resulted in remarkable clinical success in the treatment of B-cell malignancies. However, its clinical efficacy in solid tumors is limited, primarily by target antigen heterogeneity. To overcome antigen heterogeneity, we developed CAR T cells that overexpress LIGHT, a ligand of both lymphotoxin-β receptor on cancer cells and herpes virus entry mediator on immune cells. LIGHT-expressing CAR T cells displayed both antigen-directed cytotoxicity mediated by the CAR and antigen-independent killing mediated through the interaction of LIGHT with lymphotoxin-β receptor on cancer cells. Moreover, CAR T cells expressing LIGHT had immunostimulatory properties that improved the cells' proliferation and cytolytic profile. These data indicate that LIGHT"],"journal":["Cancer immunology research"],"pubmed_title":["Augmenting CAR T-cell Functions with LIGHT."],"pmcid":["PMC11444887"],"funding_grant_id":["P30 CA008748","P50 CA254838-01","P50 CA254838","R35 CA5241894","P30 CA08748-40","R35 CA241894","18181","19291"],"pubmed_authors":["Brentjens RJ","Purdon TJ","Khan JF","Souness S","Healey JH","Scheinberg DA","Meyerberg J","Rahman J","Fujino T","de Stanchina E","Rajasekhar VK","Mi X","Abrahimi P","Daniyan AF","Yoo S","McDowell JR","Tanaka K","Cai W","Mathew S","Abdel-Wahab O"],"additional_accession":[]},"is_claimable":false,"name":"Augmenting CAR T-cell Functions with LIGHT.","description":"Chimeric antigen receptor (CAR) T-cell therapy has resulted in remarkable clinical success in the treatment of B-cell malignancies. However, its clinical efficacy in solid tumors is limited, primarily by target antigen heterogeneity. To overcome antigen heterogeneity, we developed CAR T cells that overexpress LIGHT, a ligand of both lymphotoxin-β receptor on cancer cells and herpes virus entry mediator on immune cells. LIGHT-expressing CAR T cells displayed both antigen-directed cytotoxicity mediated by the CAR and antigen-independent killing mediated through the interaction of LIGHT with lymphotoxin-β receptor on cancer cells. Moreover, CAR T cells expressing LIGHT had immunostimulatory properties that improved the cells' proliferation and cytolytic profile. These data indicate that LIGHT","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-06-01T06:07:47.381Z","creation":"2026-04-08T09:53:24.89Z"},"accession":"S-EPMC11444887","cross_references":{"pubmed":["38959337"],"doi":["10.1158/2326-6066.CIR-24-0246","10.1158/2326-6066.cir-24-0246"]}}